A Phase 2 interventional study of Placebo and Prednisolone in Hypersensitivity Pneumonitis and Exogenous Allergic Alveolitis, sponsored by Matthias Griese. Terminated at 7 sites in Germany. Open to participants aged 6 Years to 25 Years. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by Matthias Griese · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Stop exogenous allergic alveolitis (EAA) or hypersensitivity pneumonitis in childhood: healthy into adulthood - a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of disease.
The hypothesis of the study is that the treatment with placebo will not be inferior in terms of Forced Vital Capacity (FVC) improvement than treatment with systemic steroids after 6 months treatment.
After an initial steroid pulse given to all patients, patients will be allocated to the two treatments, i.e., oral prednisolone and Placebo.
Experimental intervention: Placebo Control intervention: Prednisolone Duration of intervention per patient: 3 months Follow-up per patient: 3 months
Primary Objective:
To evaluate outcome of EAA at 6 months and compare the medium term treatment with systemic steroids or placebo.
Secondary Objectives:
To evaluate the completeness and knowledge of standardized and pedantic allergen elimination in families with a child with EAA.
To evaluate the treatment of EAA with systemic steroids compared to placebo at 3 months.
To evaluate the safety of the treatment of EAA with outpatient usage of systemic steroids compared to Placebo.
34 studies on the registry are indexed under Alveolitis, Extrinsic Allergic; 11 are open to participants now.
This study's enrollment of 4 is below the median of 51 across 16 interventional studies indexed under Alveolitis, Extrinsic Allergic.
Browse Alveolitis, Extrinsic Allergic studies →Matthias Griese is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Newly or previously diagnosed but not appropriately treated EAA in children, adolescents and young adults, aged between 3 and 25 years. The diagnosis of EAA must be confirmed by independent review of the findings by an expert panel and must be based on the presence of at least 4 of the following findings:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsules of placebo will be taken for 3 months, same schedule as verum.
Drug: Placebo
Oral prednisolone, anticipated dose: first month 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose. Individual capsules will be prepared using rounded dose.
Drug: Prednisolone
Administer Placebo as anti-inflammatory
Also known as: no other name
Administer Prednisolone as anti-inflammatory
Also known as: Decortin H
Forced Vital Capacity (FVC).
The relative change from baseline through month 6 compared to change from placebo of FVC.
Time frame: 6 months
Forced Vital Capacity (FVC)
FVC measured in accordance to standarized protocol.
Time frame: 3 months
Originally, it was planned to screen 60 subjects to include approximately 40 patients. From January 2015 to July 2016 due to difficulties in funding only 4 children were included in the trial. All met inclusion criteria, were randomized, and completed the trial.
| Milestone | Placebo | Prednisolone |
|---|---|---|
| Started | 1 | 3 |
| Completed | 1 | 3 |
| Not completed | 0 | 0 |
The relative change from baseline through month 6 compared to change from placebo of FVC.
| % predicted | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 |
|---|---|---|---|---|
| Forced Vital Capacity (FVC). | 126 | 103 | 84 | 65 |
FVC measured in accordance to standarized protocol.
| % predicted | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 |
|---|---|---|---|---|
| Forced Vital Capacity (FVC) | 114 | 95 | 85 | 76 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Prednisolone | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Event | Placebo | Prednisolone |
|---|---|---|
| Fever, headache, haematome, tiredness, hypertensionGeneral disorders | 1/1 | 2/3 |
| ConjunctivitisEye disorders | 1/1 | 1/3 |
| Cushing habitus, hair growth, weight gainEndocrine disorders | 1/1 | 1/3 |
| Respiratory tract infection, candidiasisInfections and infestations | 0/1 | 2/3 |
| GastritisGastrointestinal disorders | 0/1 | 1/3 |
| Age, Customized(years) | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 | Total |
|---|---|---|---|---|---|
| Number | 8.4 | 6.6 | 10.6 | 12.9 | 9.6 |
| Sex: Female, Male(Participants) | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 | Total |
|---|---|---|---|---|---|
| Female | 0 | 1 | 1 | 0 | 2 |
| Male | 1 | 0 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 1 | 1 | 1 | 4 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 | Total |
|---|---|---|---|---|---|
| Germany | 1 | 1 | 1 | 1 | 4 |
| O2 saturation at rest(%) | Prednisolone 1 | Placebo | Prednisolone 2 | Prednisolone 3 | Total |
|---|---|---|---|---|---|
| Number | 90 | 98 | 100 | 97 | 96.3 |
Plan to share: No — Equivalent to product information sheet
Ran from Apr 2015 to primary completion in Jul 2016, 15 months.
Results were first posted in Dec 2024, 8 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alveolitis, Extrinsic Allergic →